iBio (IBIO) Long-Term Debt Repayments (2023 - 2024)

iBio (IBIO) posted quarterly Long-Term Debt Repayments of $1.1 million for Q2 2024, up 147.02% quarter-over-quarter from $436000.0 in Q3 2023.

iBio (IBIO) Long-Term Debt Repayments (2023 - 2024) Analysis & Trends

iBio (IBIO) has reported Long-Term Debt Repayments for 2 consecutive years, with $1.1 million the latest figure, recorded in Q2 2024.

In Q2 2024, Long-Term Debt Repayments changed N/A year-over-year to $1.1 million; the TTM figure through Jun 2024 stood at $1.5 million (changed N/A YoY), while the FY2024 annual figure was $1.5 million, down 83.76% from the prior year.
Long-Term Debt Repayments rose to $1.1 million in Q2 2024 per IBIO's latest filing, from $436000.0 in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $1.1 million in Q2 2024 and bottomed at $436000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	17.05 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-10.01 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	iBio	172.22 Mn	172.22 Mn	-	-

Download Data